T
Thomas Foltynie
Researcher at UCL Institute of Neurology
Publications - 381
Citations - 26959
Thomas Foltynie is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 80, co-authored 352 publications receiving 21023 citations. Previous affiliations of Thomas Foltynie include University College London & University of Kent.
Papers
More filters
Journal ArticleDOI
Subthalamic nucleus gamma activity increases not only during movement but also during movement inhibition
Petra Fischer,Alek Pogosyan,Alek Pogosyan,Damian M. Herz,Damian M. Herz,Binith Cheeran,Alexander L. Green,James J. FitzGerald,Tipu Z. Aziz,Jonathan Hyam,Simon Little,Thomas Foltynie,Patricia Limousin,Ludvic Zrinzo,Peter Brown,Peter Brown,Huiling Tan,Huiling Tan +17 more
TL;DR: Investigating the role of gamma during fast stopping and recorded scalp electroencephalogram and local field potentials from deep brain stimulation electrodes in 9 Parkinson's disease patients found that STN gamma activity may support flexible motor control as it did not only increase during movement execution but also during rapid action-stopping.
Journal ArticleDOI
Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
Dilan Athauda,Kate Maclagan,Natalia Budnik,Luca Zampedri,Steve Hibbert,Iciar Aviles-Olmos,Kashfia Chowdhury,Simon S. Skene,Patricia Limousin,Thomas Foltynie +9 more
TL;DR: While patients with a range of demographic and clinical factors can potentially benefit from exenatide once‐weekly, data support an emphasis towards recruiting patients at earlier disease in future planned clinical trials of gluacagon‐like peptide‐1 (GLP‐1) receptor agonists in Parkinson's disease.
Journal ArticleDOI
Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology
Adolfo Ramirez-Zamora,James Giordano,Aysegul Gunduz,Jose D. Alcantara,Jackson N. Cagle,Stephanie Cernera,Parker Difuntorum,Robert S. Eisinger,Julieth Gomez,Sarah Long,Brandon Parks,Joshua K. Wong,Shannon Y. Chiu,Bhavana Patel,Warren M. Grill,Harrison C. Walker,Simon Little,Roee Gilron,Gerd Tinkhauser,Gerd Tinkhauser,Wesley Thevathasan,Wesley Thevathasan,Nicholas C. Sinclair,Nicholas C. Sinclair,Andres M. Lozano,Thomas Foltynie,Alfonso Fasano,Alfonso Fasano,Sameer A. Sheth,Katherine W. Scangos,Terence D. Sanger,Jonathan P. Miller,Audrey C. Brumback,Priya Rajasethupathy,Priya Rajasethupathy,Cameron C. McIntyre,Leslie Schlachter,Nanthia Suthana,Cynthia S. Kubu,Lauren R. Sankary,Karen Herrera-Ferrá,Steven Goetz,Binith Cheeran,G. Karl Steinke,Christopher W. Hess,Leonardo Almeida,Wissam Deeb,Kelly D. Foote,Michael S. Okun +48 more
TL;DR: The Seventh Annual Deep Brain Stimulation Think Tank addressed the most current use and utility of complex neurophysiological signals for development of adaptive neurostimulation to improve clinical outcomes and ethical issues arising in and from research and use of DBS.
Journal ArticleDOI
Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease
Thomas B Stoker,Thomas B Stoker,Marta Camacho,Sophie Winder-Rhodes,Ganqiang Liu,Ganqiang Liu,Clemens R. Scherzer,Thomas Foltynie,Jonathan Evans,David P. Breen,Roger A. Barker,Roger A. Barker,Caroline H. Williams-Gray +12 more
TL;DR: GBA1 variants, including those not associated with Gaucher disease, are common in PD and result in a more aggressive disease course and pathogenic and ‘non-pathogenic’ GBA1 variant were associated with the accelerated development of dementia and a moreaggressive motor course.
Journal ArticleDOI
Levodopa-induced dyskinesia in parkinson's: a longitudinal pet study
Andreas-Antonios Roussakis,Nicholas P. Lao-Kaim,Antonio Martin-Bastida,Natalie Valle-Guzman,Z Kefalopoulou,Gesine Paul-Visse,Håkan Widner,Marios Politis,Thomas Foltynie,Roger A. Barker,Paola Piccini +10 more
TL;DR: There may be a threshold of SERT-over-DAT availability in the putamen, above which PD patients are likely to become dyskinetic, as reflected by the increase of the SERT–to–DAT ratio over time.